Last reviewed · How we verify
NCT07346573
Radiotherapy Safety for Liver Malignancies Using Post-Treatment Imaging
trial testing Clinically Delivered Radiation Therapy (e.g., SBRT/IMRT) for Liver Cancer in Liver Neoplasms in 274 participants. Completed in 1 March 2025.
1 March 2025
Quick facts
| Lead sponsor | Cao peiguo |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 274 |
| Start date | 1 May 2019 |
| Primary completion | 1 March 2025 |
| Estimated completion | 1 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Clinically Delivered Radiation Therapy (e.g., SBRT/IMRT) for Liver Cancer
Conditions studied
- Liver Neoplasms — all drugs for Liver Neoplasms →
- Radiation-Induced Liver Injury — all drugs for Radiation-Induced Liver Injury →
Sponsor
Cao peiguo
Who can join
Adults 18 to 85, any sex, with Liver Neoplasms or Radiation-Induced Liver Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this retrospective observational study is to investigate the safety of radiation therapy for liver malignancies by analyzing data from patients who have already completed this treatment . The main questions it aims to answer are: What is the specific radiation dose level that leads to a visible change on CT scans called a Focal Liver Reaction (FLR)? Why do some patients develop these imaging changes while others do not, based on their scan features and clinical information? Researchers will compare patients who developed FLR with those who did not to identify the factors associated with this reaction. This study uses existing medical records and images; therefore, participants will not need to undergo any new interventions or procedures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07346573
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Neoplasms
Currently open trials in the same condition.
- NCT07377487 — TheraSphere Japan Pre-Market Study · NA · recruiting
- NCT07473687 — Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room · recruiting
- NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
- NCT07378709 — Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma · recruiting
- NCT06261814 — Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07346573 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cao peiguo
- Last refreshed: 16 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07346573.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing